Skip to main content

Table 3 Skin and muscle sodium and water content at baseline and after 6 weeks of treatment

From: SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

  Baseline Dapagliflozin vs. baseline Placebo vs. baseline
X ± SD X ± SD p-value X ± SD p-value
Skin Na + (A.U.) 24.5 ± 7.2 22.7 ± 6.4 0.013 23.8 ± 8.3 0.314
Skin H2O (A.U.) 0.153 ± 0.06 0.144 ± 0.06 0.073 0.15 ± 0.07 0.763
Na + M. triceps surae (A.U.) 20.6 ± 3.5 20.4 ± 3.7 0.801 20.3 ± 3.6 0.514
H2O M. triceps surae (A.U.) 0.513 ± 0.03 0.513 ± 0.03 0.952 0.505 ± 0.03 0.014
Body weight (kg) 87.6 ± 13 86.6 ± 13 0.001 87.6 ± 13 0.930
Urin Na + 24 h (mmol/day) 216 ± 81 210 ± 17 0.586 222 ± 104 0.660